Variants of Arachidonate 5-Lipoxygenase-activating Protein (ALOX5AP) Gene and Risk of Coronary Heart Disease: A Meta-analysis

Background and AimsPrevious studies indicated that the arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene polymorphisms are associated with risk of coronary heart disease (CHD). However, other studies have yielded contradictory results. This meta-analysis investigated the relationship between variants of arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene and CHD.MethodsWe identified all studies published before January 2010 through computer-based searches of PubMed, EMBASE, Google Scholar databases, and CNKI (Chinese National Knowledge Infrastructure). Data were extracted by two authors and pooled odds ratio (OR) and 95% confidence interval (CI) were calculated.ResultsIn this meta-analysis, HapA haplotype (rs17222814G-rs10507391T-rs4769874G-rs9551963A) was associated with myocardial infarction (MI) (OR = 1.37, 95% CI: 1.02–1.82). Regarding the HapB haplotype (rs17216473A-rs10507391A- rs9315050A- rs17222842G), there was a significant association with CHD (OR = 1.33, 95% CI: 1.10–1.62). For the rs17222814, rs10507391, rs4769874, rs9551963, rs17216473, rs9315050 and rs9579646 polymorphisms, there were no associations with CHD. For the rs17222842 polymorphism, there was a marginal association with the risk of CHD (OR = 1.17, 95% CI: 1.00–1.36).ConclusionsIn this meta-analysis, the HapB haplotype and rs1722842 polymorphism in ALOX5AP gene were associated with CHD, and the HapA haplotype was associated with risk of MI. The HapB haplotype may be a predictor to the risk of CHD.